论文部分内容阅读
目的通过观察盆腔炎方对盆腔炎性疾病后遗症雌性大鼠子宫组织、卵巢组织转化生长因子(transforming growth factor-β1,TGF-β1)及其受体Ⅱ(transforming growth factor-βreceptorⅡ,TβRⅡ)水平的影响,探讨其治疗盆腔炎性疾病后遗症的机制。方法将124只SD雌性大鼠随机抽取空白组10只、假手术组10只后造模,造模成功后按体质量随机分为盆炎方高、中、低剂量组,模型组及妇科千金胶囊组各15只。药物干预21天后,采用免疫组化法检测大鼠卵巢、子宫组织TGF-β1、TβRⅡ的表达。结果与空白组和假手术组比较,模型组子宫、卵巢组织TGF-β1、TβRⅡ表达均升高,差异有统计学意义(P<0.01)。与模型组比较,盆炎方各剂量组和妇科千金胶囊组能不同程度地降低模型大鼠子宫组织、卵巢组织TGF-β1及TβRⅡ水平,差异有统计学意义(P<0.05,P<0.01)。盆炎方各剂量组中,以高剂量组的疗效最佳,且与妇科千金胶囊相当。结论盆炎方可能通过降低盆腔炎性疾病后遗症模型大鼠子宫组织、卵巢组织中粘连修复相关指标TGF-β1及TβRⅡ的表达,缓解和消除局部炎症过程,从而治疗盆腔炎性疾病后遗症。
Objective To observe the effect of pelvic inflammatory disease on the levels of uterine tissue and transforming growth factor-β1 (TGF-β1) and its receptor Ⅱ (TβRⅡ) in female rats with sequelae of pelvic inflammatory disease Influence, explore its mechanism for the treatment of sequelae of pelvic inflammatory disease. Methods A total of 124 SD female rats were randomly divided into blank group (n = 10) and sham operation group (n = 10). After successful modeling, the rats were randomly divided into high, medium and low doses of pelvic inflammatory disease group, model group and gynecological daughter Capsule group of 15. After 21 days of drug intervention, the expression of TGF-β1 and TβRⅡ in ovary and uterus of rats was detected by immunohistochemistry. Results Compared with the blank group and the sham operation group, the expressions of TGF-β1 and TβRⅡ in the uterus and ovary of model group were significantly increased (P <0.01). Compared with the model group, each dose of the pelvic inflammatory disease group and the gynecological Qianjin capsule group could reduce the levels of TGF-β1 and TβRⅡ in the uterus tissue and ovary tissue to some extent, the difference was statistically significant (P <0.05, P <0.01) . Pot Yan prescription of each dose group, the best dose of high-dose group, and the same capsule and gynecological daughter. Conclusions Panyanfang may relieve and eliminate the local inflammatory process by reducing the expression of TGF-β1 and TβRⅡ, a marker of adhesive repair in uterine tissue and ovary tissues of sequelae of pelvic inflammatory disease, thereby treating sequelae of pelvic inflammatory disease.